Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.39 |
| ▸ | TNF | P01375 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | YAP1 | P46937 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21080225 | 1.00 | CHEK1 (0.42) | CHEK1CHEK2IRAK4TNFOPRK1 | |
| SCHEMBL21080824 | 0.84 | CHEK1 (0.45) | CHEK1CHEK2IRAK4TNFOPRK1 | |
| SCHEMBL21079892 | 0.84 | CHEK1 (0.45) | CHEK1CHEK2IRAK4TNFOPRK1 | |
| SCHEMBL4406630 | 0.83 | CHEK1 (0.47) | CHEK1CHEK2IRAK4TNFOPRK1 | |
| SCHEMBL15688851 | 0.81 | YAP1 (0.48) | CHEK1CHEK2OPRK1YAP1KDM4E | |
| SCHEMBL31678672 | 0.79 | CHEK1 (0.39) | CHEK1CHEK2IRAK4OPRK1LMNA | |
| SCHEMBL30606046 | 0.79 | CHEK1 (0.39) | CHEK1CHEK2IRAK4OPRK1LMNA | |
| SCHEMBL618287 | 0.79 | CHEK1 (0.63) | CHEK1CHEK2OPRK1 | |
| SCHEMBL21724833 | 0.78 | OPRK1 (0.46) | CHEK1CHEK2IRAK4OPRK1MAPK1 | |
| SCHEMBL30201761 | 0.78 | OPRK1 (0.46) | CHEK1CHEK2IRAK4OPRK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3583105-B1 | PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | SDHB, CYP4F2, CYP1B1 | CHEK1 3570/4885CHEK2 1841/4885IRAK4 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.